• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.

作者信息

Redjoul Rabah, Le Bouter Anne, Parinet Vincent, Fourati Slim, Maury Sébastien

机构信息

Haematology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France.

Virology Department, Assistance Publique, Hôpitaux de Paris, Henri Mondor Hospital, Créteil 94000, France.

出版信息

Lancet Haematol. 2021 Oct;8(10):e681-e683. doi: 10.1016/S2352-3026(21)00274-X. Epub 2021 Sep 3.

DOI:10.1016/S2352-3026(21)00274-X
PMID:34487683
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8415894/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c4/8415894/e4339da5fa3d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c4/8415894/e4339da5fa3d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c4/8415894/e4339da5fa3d/gr1_lrg.jpg

相似文献

1
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT.异基因造血干细胞移植受者接种第三剂BNT162b2后的抗体反应。
Lancet Haematol. 2021 Oct;8(10):e681-e683. doi: 10.1016/S2352-3026(21)00274-X. Epub 2021 Sep 3.
2
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
3
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).医护人员接种两剂 SARS-CoV-2 mRNA 疫苗（BNT162b2）后的早期抗体反应。
Clin Microbiol Infect. 2021 Sep;27(9):1351.e5-1351.e7. doi: 10.1016/j.cmi.2021.05.004. Epub 2021 May 8.
4
Blunted humoral response after mRNA vaccine in patients with haematological malignancies.血液系统恶性肿瘤患者接种mRNA疫苗后体液免疫反应减弱。
Lancet Haematol. 2021 Aug;8(8):e540-e542. doi: 10.1016/S2352-3026(21)00197-6. Epub 2021 Jul 2.
5
Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).肾移植受者对 BNT162b2（辉瑞-生物科技）接种 SARS-CoV-2 疫苗的体液免疫反应受损。
Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.
6
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
7
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.造血干细胞移植受者接种 SARS-CoV-2 疫苗后针对 SARS-CoV-2 的抗体检测：来自西班牙造血干细胞移植和细胞治疗组的前瞻性调查。
Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2.
8
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性：医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
9
Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination.异源和同源接种BNT162b2或ChAdOx1 nCoV-19疫苗后对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株的中和作用。
Cell Mol Immunol. 2021 Oct;18(10):2455-2456. doi: 10.1038/s41423-021-00755-z. Epub 2021 Aug 23.
10
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.异基因造血干细胞移植受者第二次接种BNT162b2后的抗体反应。
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.

引用本文的文献

1
Navigating uncharted waters: assessing the impact of the COVID-19 pandemic on hematopoietic stem cell transplantation: challenges and innovations.探索未知领域：评估新冠疫情对造血干细胞移植的影响：挑战与创新
Ann Med Surg (Lond). 2024 Aug 7;86(9):5416-5424. doi: 10.1097/MS9.0000000000002442. eCollection 2024 Sep.
2
Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.细胞治疗受者中对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗第三和第四剂的免疫反应：系统评价和荟萃分析。
Virol J. 2024 May 3;21(1):103. doi: 10.1186/s12985-024-02375-1.
3

本文引用的文献

1
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.异基因造血干细胞移植受者第二次接种BNT162b2后的抗体反应。
Lancet. 2021 Jul 24;398(10297):298-299. doi: 10.1016/S0140-6736(21)01594-4. Epub 2021 Jul 13.
2
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
3
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study.
多次接种mRNA-1273疫苗后造血细胞移植受者的刺突特异性记忆B细胞反应：一项纵向观察研究
Vaccines (Basel). 2024 Mar 29;12(4):368. doi: 10.3390/vaccines12040368.
4
Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.异基因造血干细胞受者中 SARS-CoV-2 疫苗剂量的疗效：系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):393-399. doi: 10.31557/APJCP.2024.25.2.393.
5
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.异基因造血干细胞移植后患者体液免疫对 COVID-19 疫苗接种的反应的影响因素和特征。
Front Immunol. 2023 May 3;14:1174289. doi: 10.3389/fimmu.2023.1174289. eCollection 2023.
6
Persistent Immunity against SARS-CoV-2 in Individuals with Oncohematological Diseases Who Underwent Autologous or Allogeneic Stem Cell Transplantation after Vaccination.接种疫苗后接受自体或异基因干细胞移植的肿瘤血液疾病患者对SARS-CoV-2的持久免疫力。
Cancers (Basel). 2023 Apr 18;15(8):2344. doi: 10.3390/cancers15082344.
7
Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.异基因造血干细胞移植后早期接种三剂重组 SARS-CoV-2 疫苗：预测高血清学反应的指标——一项前瞻性、单臂研究。
Front Immunol. 2023 Apr 19;14:1169666. doi: 10.3389/fimmu.2023.1169666. eCollection 2023.
8
Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.第三剂BNT162b2 mRNA新冠病毒疫苗显著增强异基因造血干细胞移植受者的免疫原性。
Vaccines (Basel). 2023 Mar 31;11(4):775. doi: 10.3390/vaccines11040775.
9
Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study.既往新冠病毒感染是否会影响第三次BNT162b2加强剂量后的中和抗体：一项纵向研究
Vaccines (Basel). 2023 Mar 1;11(3):560. doi: 10.3390/vaccines11030560.
10
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era.COVID-19 时代的异基因造血干细胞移植。
Front Immunol. 2023 Feb 22;14:1100468. doi: 10.3389/fimmu.2023.1100468. eCollection 2023.
实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
4
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series.实体器官移植受者接种第三剂新冠病毒疫苗的安全性和免疫原性：病例系列
Ann Intern Med. 2021 Sep;174(9):1330-1332. doi: 10.7326/L21-0282. Epub 2021 Jun 15.
5
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.COVID-19 与干细胞移植：来自 EBMT 和 GETH 多中心前瞻性调查的结果。
Leukemia. 2021 Oct;35(10):2885-2894. doi: 10.1038/s41375-021-01302-5. Epub 2021 Jun 2.
6
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.先前感染过 SARS-CoV-2 的个体对 BNT162b2 mRNA 疫苗的抗体反应。
Nat Med. 2021 Jun;27(6):981-984. doi: 10.1038/s41591-021-01325-6. Epub 2021 Apr 1.
7
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.造血干细胞移植受者 COVID-19 的临床特征和结局：一项观察性队列研究。
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
8
Antipneumococcal Seroprotection Years After Vaccination in Allogeneic Hematopoietic Cell Transplant Recipients.异基因造血细胞移植受者接种肺炎球菌疫苗后血清保护期的研究。
Clin Infect Dis. 2020 Nov 5;71(8):e301-e307. doi: 10.1093/cid/ciz1168.